Your browser doesn't support javascript.
loading
Baja prevalencia de anticuerpos antifosfolípidos autoinmunes en enfermedades hepáticas / Low prevalence of autoimmune antiphospholipid antibodies in hepatic diseases
de Larrañaga Gabriela F; Harris E, Nigel; Pierangeli, Silvia S; Alonso, Beatriz S; Schroder, Teresa; Fainboim, Hugo.
  • de Larrañaga Gabriela F; Sección Bioquímica, área Hemostasia y Trombosis. Hospital de Infecciosas F. J. Muñiz. Buenos Aires. AR
  • Harris E, Nigel; Morehouse School of Medicine. Atlanta. US
  • Pierangeli, Silvia S; Morehouse School of Medicine. Atlanta. US
  • Alonso, Beatriz S; Sección Bioquímica, área Hemostasia y Trombosis. Hospital de Infecciosas F. J. Muñiz. Buenos Aires. AR
  • Schroder, Teresa; Unidad n. 4 Hepatopatías Infecciosas. Hospital Infecciosas F. J. Muñiz. Buenos Aires. AR
  • Fainboim, Hugo; Unidad n. 4 Hepatopatías Infecciosas. Hospital Infecciosas F. J. Muñiz. Buenos Aires. AR
Medicina (B.Aires) ; 60(6): 919-922, 2000. tab
Article in Spanish | LILACS | ID: lil-305300
RESUMO
Antiphospholipid antibodies (aPL) have been associated with different diseases. They are defined as a large family of immunoglobulins (Ig) of either alloantibodies or autoantibodies. The autoimmune antibodies are associated with venous and/or arterial thrombosis, thrombocytopenia and recurrent fetal loss in the so-called antiphospholipid syndrome or in systemic lupus erythematosus. These antibodies are directed against proteins or phospholipid-protein complexes. On the contrary, antiphospholipid antibodies (alloantibodies) which are found in infectious diseases sera (syphilis, HIV, and other viral diseases), disappear with illness remission and are directed to phospholipids alone (particularly cardiolipin) and are not associated with thrombosis or recurrent fetal loss. However, the role and type of aPL found during hepatic diseases is still unclear. To investigate the prevalence of autoimmune aPL (IgG and IgM) during different hepatic diseases, we have studied 128 patients with hepatitis C virus, hepatitis B virus and hepatic autoimmune diseases without treatment as well as 40 healthy control subjects. We have used a specific ELISA kit, that uses a mixture of phospholipid instead of cardiolipin alone, and allows a better detection of aPL of the autoimmune type. Our results show that autoimmune aPL are not significantly increased in viral hepatic diseases (2%) or autoimmune diseases of the liver (3%) when compared to the control group (0%).
Subject(s)
Search on Google
Index: LILACS (Americas) Main subject: Hepatitis C / Antibodies, Antiphospholipid / Hepatitis, Autoimmune / Hepatitis B Type of study: Observational study / Prevalence study / Risk factors / Screening study Limits: Humans Language: Spanish Journal: Medicina (B.Aires) Journal subject: Medicine Year: 2000 Type: Article Affiliation country: Argentina / United States Institution/Affiliation country: Morehouse School of Medicine/US / Sección Bioquímica, área Hemostasia y Trombosis/AR / Unidad n. 4 Hepatopatías Infecciosas/AR

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: LILACS (Americas) Main subject: Hepatitis C / Antibodies, Antiphospholipid / Hepatitis, Autoimmune / Hepatitis B Type of study: Observational study / Prevalence study / Risk factors / Screening study Limits: Humans Language: Spanish Journal: Medicina (B.Aires) Journal subject: Medicine Year: 2000 Type: Article Affiliation country: Argentina / United States Institution/Affiliation country: Morehouse School of Medicine/US / Sección Bioquímica, área Hemostasia y Trombosis/AR / Unidad n. 4 Hepatopatías Infecciosas/AR